C.RIS PHARMA
C.RIS PHARMA is a company registered under SIREN number 451069884, with its registered office in SAINT-MALO. Its main activity falls under the sector: Scientific research and development. It has 2 establishments. 1 serving director is recorded in the national business register. Its reported revenue for the financial year ended in 2024 is 0 euros.
Sources: INSEE Sirene, INPI RNE, INPI, annual accounts.
Identity
- Legal form
- SARL (no further detail)
- Activity
- Research and experimental development on biotechnology (72.11Z)
- Sector
- Scientific research and development
- Headcount
- 10 to 19 employees
- Created
- 1 Jan 2004
- Share capital
- 21,840.00 EUR
- Registered with the trade register
- 9 Dec 2003
- Financial year end
- 31/12
- Establishments
- 2
Directors
- PIERRICK AUVRAY 56 years old, 02/1970 Gerant
Related companies
Companies run by the same people. Statutory auditors and liquidators are excluded: they serve in dozens of unrelated companies, and including them would draw groups that do not exist.
- SCI CELLIS via PIERRICK AUVRAY
- GROUPE CELLIS PHARMA via PIERRICK AUVRAY
Other companies at the same address
3 other company head offices are registered at this address.
Establishments
-
45106988400018 35400 SAINT-MALO
Financial strength
Financial score
56 / 100 C
Confidence: low · computed on the financial year ended 31 Dec 2024
- Equity to assets (43.3 %)
- 16.3 out of 30
- EBITDA margin
- data missing, component not taken into account
- Liquidity (302.9 %)
- 11.9 out of 20
- Debt (80.0 %)
- 7.9 out of 15
- Revenue trend
- data missing, component not taken into account
formula fin-1.0
Legal score
100 / 100 A
Confidence: high
- No insolvency proceedings
- 40.0 out of 40
- Currently trading
- 20.0 out of 20
- Age (22.9 years)
- 20.0 out of 20
- Accounts filed recently
- 20.0 out of 20
formula leg-1.0
These scores are computed by us from public data, using a published formula. They are not advice, not a guarantee, not a credit decision, and they do not replace a review of the accounts. See how it is calculated
Revenue and earnings
Detailed accounts for this company are not reproduced here, but its main aggregates are public.
Revenue Net income
| Financial year | Revenue | Change | EBITDA | Net income |
|---|---|---|---|---|
| 31 Dec 2024 | 0 € | — | 0 € | -903,668 € |
| 31 Dec 2023 | 0 € | — | 0 € | -5,850 € |
| 31 Dec 2022 | 0 € | — | 0 € | 171,522 € |
| 31 Dec 2021 | 0 € | — | 0 € | 22,865 € |
| 31 Dec 2020 | 0 € | — | 0 € | -493,021 € |
| 31 Dec 2019 | 0 € | — | 0 € | 11,911 € |
| 31 Dec 2018 | 0 € | — | 0 € | 395,082 € |
| 31 Dec 2017 | 0 € | — | 0 € | 392,437 € |
| 31 Dec 2016 | 0 € | — | 0 € | 204,909 € |
| 31 Dec 2015 | 0 € | first year on record | 0 € | 304,462 € |
Aggregates published by the French Directorate General for Enterprise, computed from accounts filed with the commercial court.
Explore similar companies
Collective agreements
Agreements declared by the employer in its payroll filings.
-
Convention collective nationale de l'industrie pharmaceutique du 6 avril 1956. Etendue par arrêté du 15 novembre 1956 JORF 14 décembre 1956.
IDCC 0176 · repealed · 1 establishment · declared in July 2026
Legal notices
-
Filing of accounts 11 Sep 2025
- Court :
- Greffe du Tribunal de Commerce de saint-malo
- Type of filing :
- Comptes annuels et rapports
- Closing date :
- 31/12/2024
BODACC C n 20250174, annonce n 4698 · Proof of publication (PDF)
-
Filing of accounts 25 Sep 2024
- Court :
- Greffe du Tribunal de Commerce de saint-malo
- Type of filing :
- Comptes annuels et rapports
- Closing date :
- 31/12/2023
BODACC C n 20240186, annonce n 2996 · Proof of publication (PDF)
-
Filing of accounts 25 Oct 2023
- Court :
- Greffe du Tribunal de Commerce de saint-malo
- Type of filing :
- Comptes annuels et rapports
- Closing date :
- 31/12/2022
BODACC C n 20230206, annonce n 2072 · Proof of publication (PDF)
-
Filing of accounts 22 Jul 2022
- Court :
- Greffe du Tribunal de Commerce de saint-malo
- Type of filing :
- Comptes annuels et rapports
- Closing date :
- 31/12/2021
BODACC C n 20220141, annonce n 4347 · Proof of publication (PDF)
-
Filing of accounts 27 Jul 2021
- Court :
- GREFFE DU TRIBUNAL DE COMMERCE DE SAINT-MALO
- Type of filing :
- Comptes annuels et rapports
- Closing date :
- 31/12/2020
BODACC C n 20210144, annonce n 2377 · Proof of publication (PDF)
-
Filing of accounts 6 Aug 2020
- Court :
- GREFFE DU TRIBUNAL DE COMMERCE DE SAINT-MALO
- Type of filing :
- Comptes annuels et rapports
- Closing date :
- 31/12/2019
BODACC C n 20200151, annonce n 5257 · Proof of publication (PDF)
-
Filing of accounts 4 Sep 2019
- Court :
- GREFFE DU TRIBUNAL DE COMMERCE DE SAINT-MALO
- Type of filing :
- Comptes annuels et rapports
- Closing date :
- 31/12/2018
BODACC C n 20190170, annonce n 1037 · Proof of publication (PDF)
Public contracts won
6 current contracts
-
Université Claude Bernard Lyon 1 553,788 € · 10 Sep 2025
Le Réseau Hospitalo-Universitaire (RHU) SyStInn porté par le Pr Dumontet et soutenu par l’Agence Nationale de la Recherche (ANR) a pour objectif d’évaluer le potentiel anticancéreu...
-
Centre Hospitalier Universitaire de Toulouse (Hôtel Dieu Saint Jacques) 2,000,000 € · 2 Apr 2025
Conduite Etudes prï¿¿cliniques ME MTI
-
CHU Nantes (Direction Générale) 200,000 € · 15 Feb 2025
Prestations pour l’évaluation de la toxicité d’un sécrétome - Étude de toxicité
-
Centre National de la Recherche Scientifique (CNRS MOY1601 Presidence) 66,300 € · 2 Aug 2024
L’objectif est d’évaluer la toxicité intraveineuse d’une dose unique du (-)(R,R)-5-FBVM (FluoroBenzoVésaMicol) nommé FBVM ci-après, pour constituer un dossier réglementaire réponda...
-
Imagine Institut des Maladies Genetiques Necker Enfants Malades 213,982 € · 25 Jul 2022
MARCHE-2022-004-Marché public relatif à l’étude réglementaire combinée de toxicité, de biodistribution et de tumorigénicité
-
Centre Hospitalier Universitaire de Toulouse (Hôtel Dieu Saint Jacques) 2,000,000 € · 11 Feb 2022
Conduite Etudes prï¿¿cliniques ME MTI
Source: essential public procurement data (DECP), Open Licence 2.0. Only the current version of each contract is shown.
Change history
- employee_range 12 → 11 4 Nov 2026
- employee_range 12 → 11 3 Nov 2026
- officer_appointed (empty) → Gerant 9 Oct 2026
Frequently asked questions about C.RIS PHARMA
- What is the SIREN number of C.RIS PHARMA?
- The SIREN number of C.RIS PHARMA is 451069884. Its intra-community VAT number is FR09451069884.
- Where is the head office of C.RIS PHARMA?
- Head office address: RUE DE LA CROIX RAUX, 35400 SAINT-MALO.
- When was C.RIS PHARMA founded?
- C.RIS PHARMA was founded on 1 Jan 2004.
- What does C.RIS PHARMA do?
- Its declared main activity is: Research and experimental development on biotechnology (NAF code 72.11Z).
- Who runs C.RIS PHARMA?
- The officer listed in the register is PIERRICK AUVRAY (Gerant).
- What is the revenue of C.RIS PHARMA?
- The latest published revenue is 0 €, for the 2024 financial year.
- How many employees does C.RIS PHARMA have?
- The declared headcount is 10 to 19 employees. Insee data for 2024.
- Is C.RIS PHARMA subject to insolvency proceedings?
- No ongoing insolvency proceedings are published in the BODACC for this company.